Grufity logoGrufity logo

Seagen Inc. Stock Research

SGEN

199.27USD+0.90(+0.45%)Market Closed

Market Summary

USD199.27+0.90
Market Closed
0.45%

SGEN Alerts

SGEN Stock Price

SGEN RSI Chart

SGEN Valuation

Market Cap

37.2B

Price/Earnings (Trailing)

-60.91

Price/Sales (Trailing)

18.94

EV/EBITDA

-66.34

Price/Free Cashflow

-70

SGEN Price/Sales (Trailing)

SGEN Profitability

EBT Margin

-30.69%

Return on Equity

-21.77%

Return on Assets

-16.61%

Free Cashflow Yield

-1.43%

SGEN Fundamentals

SGEN Revenue

Revenue (TTM)

2.0B

Revenue Y/Y

22.87%

Revenue Q/Q

3.5%

SGEN Earnings

Earnings (TTM)

-610.3M

Earnings Y/Y

15.15%

Earnings Q/Q

22.35%

Price Action

52 Week Range

105.43202.86
(Low)(High)

Last 7 days

-0.6%

Last 30 days

27.3%

Last 90 days

56.9%

Trailing 12 Months

43.6%

SGEN Financial Health

Current Ratio

3.42

SGEN Investor Care

Shares Dilution (1Y)

1.73%

Diluted EPS (TTM)

-3.3

Peers (Alternatives to Seagen)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
124.2B
26.3B
-2.34% 1.62%
18.96
4.72
1.32% 11.18%
98.0B
27.3B
-7.18% 37.83%
21.33
3.59
-0.09% -26.23%
57.1B
19.3B
-7.28% -16.95%
6.83
2.97
4.29% -31.47%
38.1B
10.2B
-3.01% 25.82%
12.5
3.74
-7.36% 95.80%
MID-CAP
9.2B
1.5B
-6.54% 2.94%
59.61
6.19
31.34% 72.43%
3.1B
108.5M
-20.63% -31.77%
-9.51
28.59
122.90% -12.19%
2.2B
60.9M
-22.54% -46.32%
-7.52
35.66
17.51% 22.00%
1.9B
107.9M
7.80% 19.42%
-3.99
17.93
54.84% 17.36%
SMALL-CAP
1.2B
112.0M
-12.49% -50.70%
-4.44
10.58
-70.76% -603.77%
1.1B
7.0M
-19.12% 19.58%
-7.01
156.87
131.81% -45.39%
507.9M
96.3M
-13.43% -85.87%
-1.8
5.27
72.44% -32.79%
499.9M
2.0B
-38.13% -92.75%
-0.76
0.25
72.89% 62.27%
278.5M
111.3M
-41.20% -71.01%
-1.45
2.5
0.54% -7.86%
98.0M
107.0K
-22.42% -85.54%
-0.91
915.57
-88.00% -52.91%
26.6M
-
29.52% -80.89%
-0.33
3.21
0.51% -185.61%

Financials for Seagen

Income Statement (Last 12 Months)
Description(%) Q/Q2022Q42022Q32022Q22022Q12021Q4
Revenue5.3%1,962,412,0001,864,113,0001,777,873,0001,668,849,0001,574,371,000
  S&GA Expenses0.6%820,963,000815,799,000785,702,000730,573,000716,190,000
  R&D Expenses4.1%1,344,361,0001,290,812,0001,365,299,0001,295,906,0001,228,672,000
Costs and Expenses3.2%2,575,382,0002,495,149,0002,514,067,0002,361,535,0002,256,427,000
EBITDA5.6%-555,588,000-588,369,000-693,551,000-644,806,000-
EBITDA Margin10.3%-0.28-0.32-0.39-0.39-
Earnings Before Taxes5.2%-602,315,000-635,461,000-739,669,000-689,525,000-675,705,000
EBT Margin10.0%-0.31-0.34-0.42-0.41-
Net Income4.2%-610,308,000-636,765,000-739,796,000-689,545,000-674,471,000
Net Income Margin9.0%-0.31-0.34-0.42-0.41-
Free Cahsflow26.2%-531,091,000-719,364,000-651,907,000-652,705,000-
Balance Sheet
(In Millions)
* denotes actual numbers (not divided by Millions)
Description(%) Q/Q2022Q42022Q32022Q22022Q12021Q4
Assets1.5%3,6753,6193,6303,6173,720
  Current Assets1.6%2,8032,7602,7792,7712,869
    Cash Equivalents-11.8%320363365261425
  Inventory17.1%427365319276201
  Net PPE7.8%248230219214210
  Goodwill0%275275275275275
  Current Liabilities12.7%818726609531569
Shareholder's Equity-0.6%2,8042,8222,9332,9983,065
  Retained Earnings-7.4%-2,154-2,006-1,815-1,680-1,544
  Additional Paid-In Capital2.7%4,9544,8254,7474,6784,608
Accumulated Depreciation-212----
Shares Outstanding0.7%187185184184183
Cashflow (Last 12 Months)
(In Millions)
Description(%) Q/Q2022Q42022Q32022Q22022Q12021Q4
Cashflow From Operations31.0%-453-657-589-590-499
  Share Based Compensation5.8%221209195179173
Cashflow From Investing-14.1%228266469394289
Cashflow From Financing52.2%12582.0086.0085.0078.00

Risks for SGEN

What is the probability of a big loss on SGEN?

72.3%


Probability that Seagen stock will be more than 20% underwater in next one year

55.4%


Probability that Seagen stock will be more than 30% underwater in next one year.

0%


Probability that Seagen stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does SGEN drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Seagen was unfortunately bought at previous high price.

Drawdowns

Returns for SGEN

Cumulative Returns on SGEN

18.6%


10-Year Cumulative Returns

28.4%


7-Year Cumulative Returns

31.4%


5-Year Cumulative Returns

26.2%


3-Year Cumulative Returns

What are the long-term rolling returns for SGEN?

FIve years rolling returns for Seagen.

Annualized Returns

Which funds bought or sold SGEN recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
2023-03-10
VICTORY CAPITAL MANAGEMENT INC
reduced
-2.97
-1,651,330
16,957,700
0.02%
2023-03-10
BAILLIE GIFFORD & CO
unchanged
-
-1,551
16,449
-%
2023-03-06
Rockefeller Capital Management L.P.
added
37.31
36,000
162,000
-%
2023-03-06
NORTH STAR ASSET MANAGEMENT INC
unchanged
-
-22,598
353,402
0.02%
2023-02-28
Voya Investment Management LLC
added
19.01
9,900,110
93,952,100
0.13%
2023-02-27
Parallax Volatility Advisers, L.P.
new
-
435,006
435,006
-%
2023-02-24
BBJS FINANCIAL ADVISORS, LLC
new
-
12,851
12,851
0.01%
2023-02-24
National Pension Service
added
9.34
906,189
26,488,400
0.05%
2023-02-24
Garde Capital, Inc.
unchanged
-
-12,000
186,000
0.02%
2023-02-24
NATIXIS
added
396
2,685,390
3,419,390
0.02%

1–10 of 46

Latest Funds Activity

Are funds buying SGEN calls or puts?
Calls
Puts
Are funds bullish or bearish(Calls - Puts)?
Net Call Options
No. of funds that own SGEN
No. of Funds

Seagen News

MarketWatch

Incyte Corp. stock remains steady Thursday, underperforms market.

MarketWatch,
58 minutes ago

InvestorPlace

InvestorsObserver

Schedule 13G FIlings of Seagen

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Mar 13, 2023
baker bros. advisors lp
25.1%
46,985,656
SC 13D/A
Feb 13, 2023
capital international investors
9.7%
18,058,081
SC 13G/A
Feb 09, 2023
vanguard group inc
6.97%
12,945,078
SC 13G/A
Feb 06, 2023
wellington management group llp
5.32%
9,881,292
SC 13G/A
Feb 01, 2023
blackrock inc.
6.4%
11,861,464
SC 13G/A
Mar 10, 2022
baker bros. advisors lp
25.6%
46,975,613
SC 13D/A
Feb 11, 2022
capital international investors
7.0%
12,778,429
SC 13G/A
Feb 04, 2022
wellington management group llp
6.36%
11,629,729
SC 13G
Feb 01, 2022
blackrock inc.
7.3%
13,341,753
SC 13G/A
May 18, 2021
baker bros. advisors lp
26.1%
47,370,508
SC 13D/A

SGEN Fair Value

Seagen fair value in different scenarios

The table shows the Fair Value estimates for Seagen for various scenarios. Disclaimer: These are just estimations from a model. None of the models are good at predicting the future. Please dont buy or sell stocks based on these outputs.
Fair ValueVery PessimisticPessimisticBase CaseOptimisticVery Optimistic
Very Low Inflation

6.67

-96.65%

10.88

-94.54%

16.92

-91.51%

23.73

-88.09%

31.02

-84.43%
Current Inflation

6.07

-96.95%

9.73

-95.12%

14.82

-92.56%

20.52

-89.70%

26.64

-86.63%
Very High Inflation

5.34

-97.32%

8.34

-95.81%

12.36

-93.80%

16.81

-91.56%

21.60

-89.16%

Historical Seagen Fair Value Estimates


Very Pessimistic Case
Pessimistic Case
Fair Value
Optimistic Case
Very Optimistic Case
Closing Stock Price

Recent SEC filings of Seagen

View All Filings
Date Filed Form Type Document
Mar 17, 2023
4
Insider Trading
Mar 17, 2023
4
Insider Trading
Mar 17, 2023
4
Insider Trading
Mar 16, 2023
4
Insider Trading
Mar 13, 2023
DEFA14A
DEFA14A
Mar 13, 2023
SC 13D/A
13D - Major Acquisition
Mar 13, 2023
DEFA14A
DEFA14A
Mar 13, 2023
DEFA14A
DEFA14A
Mar 13, 2023
DEFA14A
DEFA14A
Mar 13, 2023
8-K
Current Report

Latest Insider Trading transactions for SGEN

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
2023-03-16
LIU JEAN I
acquired
195,750
39.15
5,000
chief legal officer
2023-03-16
LIU JEAN I
sold
-999,500
199
-5,000
chief legal officer
2023-03-15
DANSEY ROGER D
sold
-1,998,120
199
-10,000
president, r&d & cmo
2023-03-15
WELCH DANIEL G
sold
-249,262
200
-1,246
-
2023-03-15
WELCH DANIEL G
acquired
79,076
38.82
2,037
-
2023-03-15
WELCH DANIEL G
sold
-471,518
200
-2,357
-
2023-03-15
DANSEY ROGER D
acquired
726,400
72.64
10,000
president, r&d & cmo
2023-03-14
WELCH DANIEL G
sold
-57,600
200
-288
-
2023-03-14
WELCH DANIEL G
sold
-108,800
200
-544
-
2023-03-14
WELCH DANIEL G
acquired
18,245
38.82
470
-

1–10 of 50

Roger D. Dansey
2680
Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment of advanced or metastatic urothelial cancer; and TUKYSA, an oral small molecule tyrosine kinase inhibitor for the treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer. It also develops TIVDAK for metastatic cervical cancer and other solid tumors; Ladiratuzumab Vedotin, an ADC targeting LIV-1 for metastatic breast cancer and solid tumors; Disitamab Vedotin, a novel HER2-targeted ADC; and SEA-CD40, SEA-TGT, SEA-BCMA, and SEA-CD70 for various cancer diseases. Seagen Inc. has collaboration agreements with Takeda Pharmaceutical Company Limited; Agensys, Inc.; Genmab A/S; Merck; and RemeGen, Co. Ltd. The company was formerly known as Seattle Genetics, Inc. and changed its name to Seagen Inc. in October 2020. Seagen Inc. was incorporated in 1997 and is headquartered in Bothell, Washington.

SGEN Income Statement

2022-12-31
Consolidated Statements of Comprehensive (Loss) Income - USD ($)
shares in Thousands, $ in Thousands
12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Revenues:   
Revenue$ 1,962,412$ 1,574,371$ 2,175,536
Costs and expenses:   
Cost of sales410,058311,565217,720
Research and development1,344,3611,228,672827,129
Selling, general and administrative820,963716,190533,835
Total costs and expenses2,575,3822,256,4271,578,684
(Loss) income from operations(612,970)(682,056)596,852
Investment and other income, net10,6556,35118,849
(Loss) income before income taxes(602,315)(675,705)615,701
Provision (benefit) for income taxes7,993(1,234)2,031
Net (loss) income$ (610,308)$ (674,471)$ 613,670
Net (loss) income per share - basic (in dollars per share)$ (3.30)$ (3.70)$ 3.51
Net (loss) income per share - diluted (in dollars per share)$ (3.30)$ (3.70)$ 3.37
Shares used in computation of per share amounts - basic (in shares)184,676182,048174,834
Shares used in computation of per share amounts - diluted (in shares)184,676182,048182,287
Comprehensive (loss) income:   
Net (loss) income$ (610,308)$ (674,471)$ 613,670
Other comprehensive income:   
Unrealized loss on securities available-for-sale, net of income tax provision of $0, $0, and $0, respectively(1,401)(211)(186)
Foreign currency translation gain, net of income tax provision of $0, $0, and $0, respectively3,732825522
Total other comprehensive income2,331614336
Comprehensive (loss) income(607,977)(673,857)614,006
Net product sales   
Revenues:   
Revenue1,706,5161,385,5661,000,598
Royalty revenues   
Revenues:   
Revenue164,554150,523126,756
Collaboration and license agreement revenues   
Revenues:   
Revenue$ 91,342$ 38,282$ 1,048,182

SGEN Balance Sheet

2022-12-31
Consolidated Balance Sheets - USD ($)
$ in Thousands
Dec. 31, 2022
Dec. 31, 2021
Current assets:  
Cash and cash equivalents$ 319,940$ 424,834
Short-term investments1,415,1301,735,202
Accounts receivable, net501,912389,256
Inventories427,211200,663
Prepaid expenses and other current assets138,340119,239
Total current assets2,802,5332,869,194
Property and equipment, net248,179210,073
Operating lease right-of-use assets46,73857,889
Intangible assets, net237,516260,593
Goodwill274,671274,671
Other non-current assets64,89547,184
Total assets3,674,5323,719,604
Current liabilities:  
Accounts payable207,851114,824
Accrued liabilities and other610,553454,030
Total current liabilities818,404568,854
Long-term liabilities:  
Operating lease liabilities, long-term43,47456,665
Other long-term liabilities8,83528,946
Total long-term liabilities52,30985,611
Commitments and contingencies
Stockholders' equity:  
Preferred stock, $0.001 par value, 5,000 shares authorized; none issued00
Common stock, $0.001 par value, 250,000 shares authorized; 186,559 shares issued and outstanding at December 31, 2022 and 183,381 shares issued and outstanding at December 31, 2021187183
Additional paid-in capital4,954,4694,607,816
Accumulated other comprehensive income3,5101,179
Accumulated deficit(2,154,347)(1,544,039)
Total stockholders' equity2,803,8193,065,139
Total liabilities and stockholders' equity$ 3,674,532$ 3,719,604